|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL) with genetic alterations of BCL-2, KMT2B, and KMT6.
|
30693983 |
2019 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
A recent phase I first-in-human study of the BCL-2 inhibitor venetoclax in non-Hodgkin lymphoma showed an overall response rate of 44%.
|
29666304 |
2018 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mechanism of action of EBV, Bcl-2, p53, c-Myc and Rb in non-Hodgkin's lymphoma.
|
27049262 |
2016 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thirty-two patients diagnosed with non-Hodgkin lymphoma with concurrent MYC and BCL2 translocations from 2003 to 2013 were identified.
|
25656914 |
2015 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
CTD_human |
Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma.
|
26239085 |
2015 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNA was extracted from archival CPs of B-cell NHL cases with previous fluorescence in situ hybridization (FISH) assays for MYC rearrangement and/or IGH/BCL-2 translocation.
|
25807917 |
2015 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Role of polymorphisms in BCL-2 and BAX genes in modulating the risk of developing non-Hodgkin lymphoma.
|
24024471 |
2014 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
MYC/BCL2 double hit lymphoma (DHL) is a rare, recently recognised and highly aggressive subtype of non-Hodgkin lymphoma, with an affinity to involve the central nervous system and the head and neck either at initial presentation or during relapse.
|
23932423 |
2014 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
|
20352431 |
2010 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
This indicates that primers for bcl-2 gene must include icr primer, whenever the bcl-2 gene is being evaluated for B-cell NHL in this part of the world and this might reduce the variability of frequency of bcl-2 gene rearrangement within and between different regions.
|
19537891 |
2009 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma.
|
18929412 |
2009 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Some evidence suggests that IL-10 might be associated with the progression of T-cell NHLs and that IL-10 may be involved in a rescue effect, protecting T cells from apoptotic cell death associated with upregulated bcl-2 expression.
|
17408400 |
2007 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multiplex PCR for the detection of BCL-1/IGH and BCL-2/IGH gene rearrangements--clinical validation in a prospective study of blood and bone marrow in 258 patients with or suspected of non-Hodgkin's lymphoma.
|
17438702 |
2007 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 has been implicated in conferring resistance to chemotherapy in non-Hodgkin's lymphoma and is therefore a candidate prognostic marker in DLBCL.
|
16796775 |
2006 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ongoing clinical trials are exploring the role of Bcl-2 downregulation with oblimersen (Bcl-2 antisense) in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma.
|
15784299 |
2005 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, two other genes, BCL6 and BCL2, which are classically related to apoptosis and non-Hodgkin lymphoma, were shown for the first time to be involved in amplification.
|
15611930 |
2005 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Incidence of BCL-2 gene rearrangements in Argentinean non-Hodgkin lymphoma patients: increased frequency of breakpoints outside of MBR and MCR.
|
14757440 |
2004 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
|
15651174 |
2004 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.
|
10784621 |
2000 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.
|
10873104 |
2000 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study was planned with the aim to investigate the association between bcl-2 gene rearrangements and apoptotic changes during chemotherapy in patients with non-Hodgkin's lymphoma.
|
10074891 |
1999 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The t(14;18)(q32;q21) translocation, involving the BCL2 gene and junctional segments (JH) of the immunoglobulin heavy chain gene (IGH), constitutes the most common chromosomal translocation in non-Hodgkin's lymphoma of B-cell type.
|
9443038 |
1998 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, in another series of 11 patients and a NHL cell line, we demonstrated t(14;18) and t(11;14) in interphase and metaphase cells with a combination of BCL2 (or PRAD1) with IgH gene probes.
|
9209369 |
1997 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate an IGL-mediated rearrangement of an unknown gene at 9q34 that together with BCL2 and MYC might be involved in the lymphomagenesis of the present case of FCCL and perhaps in other cases of non-Hodgkin lymphoma in which t(9;22) is sporadically occurring.
|
9331562 |
1997 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In order to clarify the effects of Epstein-Barr virus (EBV) infection on apoptosis and proliferative activity of non-Hodgkin's lymphoma, 135 Japanese lymphoma cases were investigated for the presence of viral RNA and its correlation with bcl-2 protein (Bcl-2) expression.
|
9260592 |
1997 |